Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
RE: NIH director tweeting about interferon11 Feb 2022 07:13
And then this activ2 presentation Monday which is an NIH backed trial. It’s as if they are prepping/waving the flag before the day hmmmm https://www.eurekalert.org/news-releases/942698
gggg21
Posted in: SNG
Posts: 8,927
Price: 190.50
No Opinion
NIH director tweeting about interferon11 Feb 2022 06:58
https://twitter.com/nihdirector/status/1491887417535737860?s=21
In ~10% of cases, #SARSCoV2 infection triggers oxygen-deficient #COVID19 pneumonia. New #NIH-funded research suggests insufficient type 1 IFN immunity in the respiratory tract may account for viral spread, leading to pulmonary & systemic inflammation.
CREDIT GGG21 ON SNG board..
Interferon-ß acts directly on T cells to prolong allograft survival by enhancing regulatory T cell i12 Feb 2022 20:12
Looks to be a newly published study, full details behind a paywall, but the summary seems pretty good if you've got a product that can deliver INFb to the human body without the side effects associated with subcutaneous administration...
" Highlights
•
IFNß synergizes with CTLA-4 Ig to prolong allograft survival by promoting Treg cells
•
IFNß directly acts on T cells to enhance Treg cell induction
•
IFNß activates STAT1 signaling to promote P300 expression and increase Foxp3 acetylation
Summary
Type I interferons (IFNs) are pleiotropic cytokines with potent antiviral properties that also promote protective T cell and humoral immunity. Paradoxically, type I IFNs, including the widely expressed IFNß, also have immunosuppressive properties, including promoting persistent viral infections and treating T-cell-driven, remitting-relapsing multiple sclerosis. Although associative evidence suggests that IFNß mediates these immunosuppressive effects by impacting regulatory T (Treg) cells, mechanistic links remain elusive. Here, we found that IFNß enhanced graft survival in a Treg-cell-dependent murine transplant model. Genetic conditional deletion models revealed that the extended allograft survival was Treg cell-mediated and required IFNß signaling on T cells. Using an in silico computational model and analysis of human immune cells, we found that IFNß directly promoted Treg cell induction via STAT1- and P300-dependent Foxp3 acetylation. These findings identify a mechanistic connection between the immunosuppressive effects of IFNß and Treg cells, with therapeutic implications for transplantation, autoimmunity, and malignancy."
https://www.cell.com/immunity/ppt/S1074-7613(22)00040-1.ppt
Credit to Brand on SNG Board..
Just to say for those unaware of this ..
Check out Synairgen .. If P3 is a success then many multiples of current SP
Check out Broker predictions... There are some well informed posters
on the SNG board here.....Good Luck..!! Check out the Buys on Friday 11/02
Over £1million in last 25mins... Polygon have recently increased to over 18%..
Totally disagree LEFKOSIA.....
AIM companies are destroyed by shorters....they
turn off investors....and strifle new business....
I sold out of IQE because shorters have the sp
under complete control.....If you were trying to get
a new business off the ground on AIM would
you be happy to see shorters deter investment???
For my outsider bet I am going for Vieux Lion Rouge...currently 50/1 EW
Has a good chance of place IMO.....GL Some very good odds on some
good chancers today....
Manifesto was the first horse to win the National twice....1897 1899..LOL!
JOG has 250 posts so far today, but top of my Hot Chat Topics
is BMN with 151...Followed by SEE with 127....do we all get to
see the same stocks in that menu.......why does JOG not appear?
I would have thought it was the most popular most posts but seems
they are selected...by who?